Solu Therapeutics Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$41M
- Investors
-
10
Solu Therapeutics General Information
Description
Developer of bifunctional small-molecule therapeutics designed to eliminate disease-driving cells. The company's platform combines selective small-molecule binders with proprietary antibodies and provides oncology therapeutics, eliminating cells that drive inflammatory and autoimmune diseases, enabling medical professionals to improve specificity and efficacy through deep binding pockets and reduce safety risks.
Contact Information
Website
www.solutherapeutics.comCorporate Office
- 15 Necco Street
- 7th Floor
- Boston, MA 02210
- United States
Corporate Office
- 15 Necco Street
- 7th Floor
- Boston, MA 02210
- United States
Solu Therapeutics Timeline
Solu Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series A) | 09-Apr-2025 | $41M | Completed | Clinical Trials - Phase 1 | ||
| 1. Seed Round | 16-Sep-2023 | Completed | Clinical Trials - Phase 1 |
Solu Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Solu Therapeutics Comparisons
Industry
Financing
Details
Solu Therapeutics Competitors (43)
One of Solu Therapeutics’s 43 competitors is Synthekine, a Venture Capital-Backed company based in Menlo Park, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Synthekine | Venture Capital-Backed | Menlo Park, CA | ||||
| Nexo Therapeutics | Venture Capital-Backed | Littleton, CO | ||||
| Athos Therapeutics | Venture Capital-Backed | Los Angeles, CA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Neurona Therapeutics | Formerly VC-backed | South San Francisco, CA |
Solu Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Solu Therapeutics Patents
Solu Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026064344-A1 | Heterobifunctional molecules for binding mrgx2 and methods of treating medical conditions using same | Pending | 17-Sep-2024 | ||
| WO-2026024976-A1 | Methods of treating leukemia using cytotoxicity targeting chimeras for ccr2-expressing cells | Pending | 24-Jul-2024 | ||
| WO-2026006182-A1 | Heterotrifunctional molecules for binding nav1.7 and nav1.8 and methods of treating medical conditions using same | Pending | 24-Jun-2024 | ||
| WO-2025208006-A1 | Heterobifunctional molecules for binding na v1.7 and methods of treating medical conditions using same | Pending | 29-Mar-2024 | ||
| WO-2025208012-A1 | Heterobifunctional molecules for binding na v1.8 and methods of treating medical conditions using same | Pending | 29-Mar-2024 | C07D401/14 |
Solu Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Solu Therapeutics Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Biovision Ventures | Venture Capital | Minority | ||
| Hengdian Group Capital (HgC) | Corporate Venture Capital | Minority | ||
| Lilly USA | Corporation | Minority | ||
| Pappas Capital | Venture Capital | Minority | ||
| Therapy Acceleration Program (TAP) | Not-For-Profit Venture Capital | Minority |
Solu Therapeutics FAQs
-
When was Solu Therapeutics founded?
Solu Therapeutics was founded in 2022.
-
Where is Solu Therapeutics headquartered?
Solu Therapeutics is headquartered in Boston, MA.
-
What is the size of Solu Therapeutics?
Solu Therapeutics has 7 total employees.
-
What industry is Solu Therapeutics in?
Solu Therapeutics’s primary industry is Drug Discovery.
-
Is Solu Therapeutics a private or public company?
Solu Therapeutics is a Private company.
-
What is the current valuation of Solu Therapeutics?
The current valuation of Solu Therapeutics is .
-
What is Solu Therapeutics’s current revenue?
The current revenue for Solu Therapeutics is .
-
How much funding has Solu Therapeutics raised over time?
Solu Therapeutics has raised $72M.
-
Who are Solu Therapeutics’s investors?
Biovision Ventures, Hengdian Group Capital (HgC), Lilly USA, Pappas Capital, and Therapy Acceleration Program (TAP) are 5 of 10 investors who have invested in Solu Therapeutics.
-
Who are Solu Therapeutics’s competitors?
Synthekine, Nexo Therapeutics, Athos Therapeutics, Adaptimmune Therapeutics, and Neurona Therapeutics are some of the 43 competitors of Solu Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
